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Introduction {#sec0005}
============

*Acinetobacter baumannii* healthcare associated infections (HAIs) are considered a serious public health problem owing to their prevalence and mortality in developing countries.[@bib0135], [@bib0140] The susceptibility of *A. baumannii* to the most commonly used antibiotics has decreased.[@bib0145]

The treatment of carbapenem-resistant *A. baumannii* (CR-AB) has been a challenge because carbapenem is the first option in most hospitals for empirical treatment of HAI. Consequently, older drugs with increased toxicity, including polymyxins and aminoglycosides, have been used based solely on empirical evidence.[@bib0150] Doxycycline is an oral tetracycline with activity against *A*. *baumannii* and this drug can achieve therapeutic levels in cerebrospinal fluid when adequate dosage is used.[@bib0155] Tigecycline is another option approved for intra-abdominal and soft tissue infections that has also been used extensively for the treatment of multidrug resistant infections at other anatomic locations. Unfortunately, clinical and antimicrobial susceptibility data are rarely evaluated together, so the true efficacy of non-carbapenem antibiotics against CR-AB is unknown. The aims of this study were to characterize the molecular types of *A. baumannii* isolates from cerebrospinal fluid and blood culture and to evaluate clinical data and susceptibility patterns of these isolates to treatment with polymyxin, colistin, tigecycline, doxycycline, meropenem, and imipenem.

Material and methods {#sec0010}
====================

Study setting {#sec0015}
-------------

A transversal study was carried out at Hospital Universitario Evangelico de Curitiba (HUEC), a tertiary-care, trauma reference hospital, in Southern Brazil, with a total number of 660 beds. The study included patients admitted from April 2010 through April 2013. This study was approved by the Ethics Committee of FEPAR and FPP (311.769).

Clinical data {#sec0020}
-------------

Data were collected from medical charts and/or hospital computer system databases. The clinical data evaluated included age, gender, site of infection, comorbidities, admission at intensive care unit, antimicrobial therapy, and outcome. Antimicrobial therapy was included in the analysis when it was started within 72 h of infection diagnosis. Infections where classified according to CDC criteria.[@bib0160] Thirty-day mortality was also analyzed.

Microbiological studies {#sec0025}
-----------------------

Twenty-six isolates of *A. baumannii* from 23 patients admitted at HUEC from April 2010 through April 2013 were evaluated. Nineteen isolates were obtained from blood culture and 7 from cerebrospinal fluid culture. All isolates were identified using the Vitek2^®^ Compact System (bioMérieux, Durham, USA) and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF) using Biotyper 2.0 software (Bruker151 Daltonik Inc, Bremen, Germany).

Antibiotic susceptibility tests {#sec0030}
-------------------------------

Minimal inhibitory concentration (MIC) of colistin, doxycycline, imipenem, meropenem, polymyxin B and tigecycline was estimated by the agar dilution method according to the CLSI, M7-A9 approved standard.[@bib0165] Polymyxin B and colistin were also tested by a broth microdilution method according to CLSI M7-A9.[@bib0170] Interpretation of MIC was performed according to CLSI, M100-S24,[@bib0175] except for tigecycline.[@bib0180] The MIC~50~ and MIC~90~ were calculated for both the agar and broth methods. We also compared broth and agar dilution for colistin and polymyxin using a concordance level of ±≤1 log~2~.[@bib0185]

Molecular detection of oxacillinase genes {#sec0035}
-----------------------------------------

To determine oxacillinase-encoding genes, polymerase chain reaction (PCR) was performed for all isolates by using the following primers: *bla*~OXA-23~ (F-5′ GATCGGATTGGAGAACCAGA 3′; R-5′ ATTTCTGACCGCATTTCCAT 3′), *bla*~OXA-51~ (F-5′ TAATGCTTTGATCGGCCTTG 3′; R-5′ TGGATTGCACTTCATCTTGG 3′), *bla*~OXA-58~ (F-5′ AAGTATTGGGGCTTGTGCTG 3′; R-5′ CCCCTCTGCGCTCTACATAC 3′), *bla*~OXA-143~ (F-5′ TGGCACTTTCAGCAGTTCCT 3′; R-5′ TAATCTTGAGGGGGCCAACC 3′). PCR was performed in a final volume of 25 μL with a final DNA concentration of 100 ng/mL. The amplification conditions were 94 °C for 25 s, followed by 52 °C for 40 s and 72 °C for 50 s.[@bib0190]

Pulsed field gel electrophoresis (PFGE) {#sec0040}
---------------------------------------

All 26 isolates were genotyped by PFGE and DNA was prepared as described previously.[@bib0195] The entire chromosomal DNA of the strains was digested with 30 U of *Apa*I (Fermentas -- Life Science, Glen Burnie, MD). PFGE was performed by using a clamped homogeneous electric field electrophoresis (CHEF) DRIII apparatus (Bio-Rad Laboratories, Hercules, USA). The conditions employed were as follows: temperature of 12 °C, voltage of 6 V/cm, run time of 30 h, and switch time of 5--35 s. The pattern of bands was interpreted according to previously described criteria.[@bib0200] PFGE clustering was determined by using the unweighted-pair group method with arithmetic averages (UPGMA) and by using Dice\'s coefficient. The tolerance was set at 1%. Identical isolates were assigned the same capital letter. Those with 80% similarity were assigned as a subtype of the major type, followed by an Arabic number (e.g. A1, A2, A3, A4).

Results {#sec0045}
=======

Patient data {#sec0050}
------------

Twenty-six isolates from 23 patients were evaluated. The median age of patients was 42 years (10--60 years). All patients were hospitalized in the intensive care unit when clinical samples were collected. Isolates were obtained from blood culture or cerebrospinal fluid. Samples from other body sites (sputum or bronchoalveolar lavage, urine or tissue biopsy) were not evaluated. Clinical characteristics are presented in [Table 1](#tbl0005){ref-type="table"}.Table 1Clinical and laboratorial data from 23 patients with *Acinetobacter baumannii* causing infection.Table 1N[e](#tblfn0025){ref-type="table-fn"}SexAgeSite of infectionDiseaseHAI[c](#tblfn0015){ref-type="table-fn"}OutcomeTreatment[b](#tblfn0010){ref-type="table-fn"}^,^[d](#tblfn0020){ref-type="table-fn"}Broth dilution methodAgar dilutionIPMMEMDCTGCCOLPOLCOLPOLPFGEC3F54MeningitisNeoplasmYesDeathMEM, VAN, SXT, AK\>32\>32110.5≤0.250.50.125D1C6M23MeningitisTraumaYesDeathAK, TGC\>32\>32120.50.520.25A11C8F41MeningitisNeoplasmYesDeathMEM, VAN, POL\>32\>32≤0.520.5≤0.2510.25A5C7M22MeningitisTraumaYesDeathAK, TGC, IPM\>32\>32≤0.5210.510.5C3C9\>32\>321210.511A6H14\>32\>32≤0.520.5≤0.2510.5G1C10M41MeningitisHydrocephalusYesDeathRIF, COL0.50.5≤0.50.510.521E2C11F20MeningitisHead traumaYesDeathMEM, VAN, POL\>32\>321210.510.5B1H2M42VAP[a](#tblfn0005){ref-type="table-fn"}Acute Lymphocytic LeukemiaYesSurvivalIPM, VAN32\>321210.510.5F3H7M49VAPAcute Lymphocytic LeukemiaYesDeathIPM, VAN\>32\>32121210.5A9H8M49SSTIHemorragic strokeYesDeathRIF, TZP, VAN, POL\>32\>32≤0.5210.521H1H9F10BacteremiaBurnYesSurvivalAK0.1250.25≤0.50.51≤0.2510.5C1H10F46VAPUreteral calculusYesSurvivalLZD, MEM\>32\>32≤0.521110.5C2H18\>32\>32≤0.520.5≤0.2510.25A10H11M41BacteremiaMyelodysplasic syndromeYesDeathLZD, MEM\>32\>32120.50.510.5A3H13M42BacteremiaRenal transplantNoSurvivalCIP\>32\>321210.511A3H15M75VAPTraumaYesDeathETP\>32\>321210.520.25A7H16M88BacteremiaTraumaYesDeathTZP\>32\>32120.5≤0.2510.5A7H17F51VAPTraumaYesDeathIPM, LZD, SXT, POL\>32\>32≤0.520.5≤0.2510.5A8H19M52VAPAcute renal failureYesDeathIPM, VAN\>32\>321110.510.5E1H20M31SSTITraumaYesDeathMEM, VAN, POL\>32\>32121≤0.2510.25A1H21M68VAPSarcoidosisYesDeathIPM, LZD\>32\>32121≤0.2510.25A4H22M32SSTITraumaYesSurvivalRIF, LZD, MEM, POL\>32\>32≤0.520.50.510.25A2H24M78UTIAcute infarctYesSurvivalTZP, MEM, POL\>32\>32121111F1H25M68VAPChronic renal failureYesDeathMEM, LZD\>32\>32840.5≤0.2510.5F1H26M38VAPHIV infectionYesDeathPOL, MEM\>32\>328410.510.5F2[^2][^3][^4][^5][^6]

Meningitis {#sec0055}
----------

Six patients presented with nosocomial meningitis. The median age was 33 years (15--56 years) with 3 females and 3 males. All patients presented with meningitis secondary to external ventricular shunt due to head trauma or neoplasm with a mortality rate of 100%. All strains in these patients were susceptible to polymyxins (colistin and polymyxin) and doxycycline. When bacterial susceptibility to polymyxins was taken into account, 3 patients received the correct treatment. The 3 remaining patients were treated with carbapenems, and the MIC of this antibiotic was determined to be \>32 mg/L in all strains isolated from these patients. There was no clonality shared among the meningitis cases. In one patient with *A. baumannii* meningitis, the clone isolated from cerebrospinal fluid was identical to one found in blood culture and another cerebrospinal fluid sample that was obtained 5 days later (Clone A).

Bacteremia {#sec0060}
----------

Seventeen patients presented with *A. baumannii* bacteremia, 4 of them primary and 13 of them secondary to infection at another site. Ventilator-associated pneumonia (VAP) with secondary bacteremia was the most common infection (9 cases), followed by secondary bacteremia caused by skin and soft tissue infection (3 cases) and urinary tract infection (1 case). The median age of patients was 50 years (10--60 year), with 14 males and 3 females. There was no clonal association with a specific site of infection. Considering the therapeutic and microbiological aspect of bacteremic patients, 7 patients received correct therapy within 72 h (41.17%). The mortality of patients with *A. baumannii* bacteremia was 64.70%; specifically, 7 of 9 patients with VAP, and 1 of 3 with skin-soft tissue infections died. There was no correlation of survival with correct antibiotic therapy within first hours of culture sample. There was no clonality among cases of *A. baumannii* bacteremia.

Antimicrobial susceptibility {#sec0065}
----------------------------

More than 90% of isolates were resistant to carbapenem (MIC~50~ and MIC~90~ \> 32 μg/mL).

Isolates were susceptibility to polymyxin and colistin (MIC~50~ and MIC~90~ = 1 μg/mL for polymyxin; MIC~50~ = 0.5 μg/mL and MIC~90~ = 1 μg/mL for colistin). Broth and agar dilutions for colistin and polymyxin susceptibility showed a high concordance level (100%).

Bacterial isolates also had susceptibility to tigecycline and doxycycline (MIC~50~ and MIC~90~ = 1 μg/mL for tigecycline; MIC~50~ and MIC~90~ = 2 μg/mL for doxycycline). Only two samples were resistant to these drugs.

PCR amplified *bla*~OXA-51~ in all isolates. The *bla*~OXA-23~ gene was amplified in all 24 isolates resistant to carbapenem, but was not detected in the two isolates susceptible to carbapenem.

PFGE {#sec0070}
----

Molecular typing with PFGE revealed 8 distinct patterns with 80% similarity (see dendrogram, [Fig. 1](#fig0005){ref-type="fig"}). Thirteen isolates belong to pattern A (50%), including 11 subtypes. Other patterns (B, C, D, E, F, G and H) were found in 1, 3, 1, 2, 4, 1 and 1 samples, respectively. Both isolates of carbapenem-susceptible *A. baumannii* showed 70.3% similarity (patterns G and H)Fig. 1Dendrogram of 26 isolates from 23 patients with *Acinetobacter baumannii* causing infection. See [Table 1](#tbl0005){ref-type="table"} to correlation of isolates and site of infection.

Discussion {#sec0075}
==========

Carbapenem-resistant *A. baumannii* infections are severe and result in high mortality in critically ill patients. All patients with meningitis ultimately died despite adequate therapy, a mortality rate previously described by our group.[@bib0205] The outcome is not different for bacteremia, although previous studies have shown that delay in the adequate therapy can reduce the mortality.[@bib0210] Carbapenem-resistant *A. baumannii* is becoming increasingly prevalent in Brazil, and more than 60% of strains in some areas are resistant. OXA-23 carbapenemase has been described as endemic since 2003 in Southern Brazil[@bib0215] and was identified in all carbapenem-resistant *A. baumannii* in other publications.[@bib0220] The current study confirms that this oxacillinase is prevalent and probably the main mechanism of carbapenem resistance. However, isolates from some hospitals have a different carbapenemase profile, including a low prevalence of OXA-23 in *A. baumannii*.[@bib0225]

Out of 26 isolates, 24 were susceptible to doxycycline and two isolates showed intermediate resistance. Timurkaynak et al. found a similar doxycycline susceptibility pattern in *A. baumannii*,[@bib0230] this drug has a bactericidal effect against *A. baumannii* in some isolates, including carbapenem-resistant strains.[@bib0235] Although minocycline has been more potent against *Acinetobacter*, this tetracycline is not available in Brazil.

In our study, there was a high concordance between susceptibility to colistin and polymyxin, but we did not test resistant isolates. Similar results were described by Gales et al., who reported 94.3% concordance in susceptibility to these drugs.[@bib0185] Furthermore, among the 26 isolates of *A. baumannii*, 5 showed skipped well phenomena for colistin and 8 for polymyxin (data not shown). This phenomenon occurs when these drugs are tested in broth microdilution and is associated with hetero-resistance.[@bib0240]

PFGE demonstrated a predominant clone (A) with the remaining isolates characterized as related clones. The mechanism of carbapenem resistance was associated with the presence of the gene *bla*~OXA-23~, although we cannot exclude combined mechanisms such as pump efflux and porin loss.[@bib0245]

The question of whether to use combined therapy to treat *Acinetobacter* infections remains unanswered. In vitro studies are controversial and clinical studies are comprised of retrospective cohorts with small sample numbers. However, in the context of multidrug-resistant *Acinetobacter*, few options are available, mainly for hard-to-treat infections, like meningitis. Tigecycline has a low penetration into cerebrospinal fluid.[@bib0250] Tigecycline is also contra-indicated for the treatment of primary bacteremia as peak concentration of less than 1 mg/L can be achieved, an insufficient level for treatment of bloodstream infection. Furthermore, sub-therapeutic concentrations are associated with increasing resistance.[@bib0255] Polymyxin is the drug primarily used for treatment of CR-AB. The use of polymyxin B is less reported than that of colistin, although this drug has shown successful results with less acute renal injury than colistin.[@bib0260] However, to date, there are no reports regarding the penetration of polymyxin B, the most common polymyxin used in Brazil, in the central nervous system. Colistin has been used for the treatment of meningitis with reasonable outcomes.[@bib0260] Despite the presence of a susceptibility pattern to polymyxins in most of our isolates, these drugs should be cautiously used due to increasing resistance, nephrotoxicity, and neurotoxicity. When these drawbacks are taken into consideration, doxycycline is an attractive alternative for or potential addition to other active drugs to treat nosocomial meningitis.

In summary, *A. baumannii* infections in our patient cohort resulted in high mortality, and carbapenem resistance was frequent in these severe infections. OXA-23 continues to be the main mechanism of resistance of *A. baumannii* in this region of the Brazil, with a predominant clonal pattern. Fortunately, alternative drugs are available for use under specific conditions that must be decided by experts.
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[^2]: VAP, ventilator-associated pneumonia; UTI, urinary tract infection; SSTI, skin and soft tissue infection.

[^3]: Therapy within 72 h of diagnosis of HAI.

[^4]: HAI, hospital-acquired infection.

[^5]: IPM, imipenem; MEM, meropenem; COL, colistin; POL, polymyxin; DC, doxycycline; AK, amikacin; LZD, linezolid; ETP, ertapenem; VAN, vancomcycin; TZP, piperacillin-tazobactam; SXT, sulfamethoxazole/trimetoprim; CIP, ciprofloxacin; RIF, rifampin.
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